CXCL1/CXCR2 signaling in pathological pain: Role in peripheral and central sensitization
- PMID: 28587921
- DOI: 10.1016/j.nbd.2017.06.001
CXCL1/CXCR2 signaling in pathological pain: Role in peripheral and central sensitization
Abstract
Pathological pain conditions can be triggered after peripheral nerve injury and/or inflammation. It is associated with plasticity of nociceptive pathway in which pain is prolonged even after healing of the injured tissue. Generally combinations of analgesic drugs are not sufficient to achieve selective palliation from chronic pain, besides causing a greater number of side effects. In order to identify novel alternatives for more effective treatments, it is necessary to clarify the underlying mechanisms of pathological pain. It is well established that there are two main components in pathological pain development and maintenance: (i) primary sensory neuron sensitization (peripheral sensitization), and (ii) central sensitization. In both components cytokines and chemokines act as key mediators in pain modulation. CXCL1 is a chemokine that promote both nociceptor and central sensitization via its main receptor CXCR2, which is a promising target for novel analgesic drugs. Here, we reviewed and discussed the role of the CXCL1/CXCR2 signaling axis in pathological pain conditions triggered by either peripheral inflammation or nerve injury.
Keywords: CXCL1; CXCR2; Chemokine; Inflammatory pain; Neuropathic pain.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1/CXCR2 signaling pathway.Neuropharmacology. 2018 Jun;135:34-47. doi: 10.1016/j.neuropharm.2018.03.004. Epub 2018 Mar 5. Neuropharmacology. 2018. PMID: 29518397
-
Chemokine receptor CXCR2 in dorsal root ganglion contributes to the maintenance of inflammatory pain.Brain Res Bull. 2016 Oct;127:219-225. doi: 10.1016/j.brainresbull.2016.09.016. Epub 2016 Sep 30. Brain Res Bull. 2016. PMID: 27697507
-
The role of CXCL1/CXCR2 axis in neurological diseases.Int Immunopharmacol. 2023 Jul;120:110330. doi: 10.1016/j.intimp.2023.110330. Epub 2023 May 27. Int Immunopharmacol. 2023. PMID: 37247498 Review.
-
Spinal blockage of CXCL1 and its receptor CXCR2 inhibits paclitaxel-induced peripheral neuropathy in mice.Neuropharmacology. 2019 Jun;151:136-143. doi: 10.1016/j.neuropharm.2019.04.014. Epub 2019 Apr 13. Neuropharmacology. 2019. PMID: 30991054
-
Neuropathic Pain: Sensory Nerve Injury or Motor Nerve Injury?Adv Exp Med Biol. 2016;904:59-75. doi: 10.1007/978-94-017-7537-3_5. Adv Exp Med Biol. 2016. PMID: 26900063 Review.
Cited by
-
Neuroinflammation in HIV-Related Neuropathic Pain.Front Pharmacol. 2021 Apr 20;12:653852. doi: 10.3389/fphar.2021.653852. eCollection 2021. Front Pharmacol. 2021. PMID: 33959022 Free PMC article. Review.
-
Liquiritin Alleviates Pain Through Inhibiting CXCL1/CXCR2 Signaling Pathway in Bone Cancer Pain Rat.Front Pharmacol. 2020 Apr 24;11:436. doi: 10.3389/fphar.2020.00436. eCollection 2020. Front Pharmacol. 2020. PMID: 32390832 Free PMC article.
-
Neuraxial Cytokines in Pain States.Front Immunol. 2020 Jan 28;10:3061. doi: 10.3389/fimmu.2019.03061. eCollection 2019. Front Immunol. 2020. PMID: 32047493 Free PMC article. Review.
-
The Role of ERK1/2 Pathway in the Pathophysiology of Alzheimer's Disease: An Overview and Update on New Developments.Cell Mol Neurobiol. 2023 Jan;43(1):177-191. doi: 10.1007/s10571-022-01191-x. Epub 2022 Jan 17. Cell Mol Neurobiol. 2023. PMID: 35038057 Free PMC article. Review.
-
Chemokine receptor CXCR2 in primary sensory neurons of trigeminal ganglion mediates orofacial itch.Front Mol Neurosci. 2023 Oct 26;16:1279237. doi: 10.3389/fnmol.2023.1279237. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37953876 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical